Bullish & Foolish
Full DMRA fundamentals All 466 on the Survival Watch

DMRADAMORA THERAPEUTICS, INC.

Is Damora Therapeutics struggling financially?

Yes, by its own account. Damora Therapeutics told the SEC on 19 Mar 2026, in Form 10-K, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Mar 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$1.9B
Source filing
10-K 19 Mar 2026
Balance sheet
30 Jun 2026

Cash runway

78+ mo

Runs out some time after Dec 2032, raising nothing.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$540.5M

÷

Cash burned over the last 12 months

$69.8M

What Damora Therapeutics told the SEC

…need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern. We may be required to seek additional funds sooner than planned through public or private equity offerings, debt financings, collaborations and licensing arrangements or other…

DAMORA THERAPEUTICS, INC., Form 10-K, filed 19 Mar 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 3488.5% share-count increase The company issued stock. Each share now owns 97.2% less of the business than a year ago, before any change in the price.
  • Cash burn is increasing It is spending 171% more cash per year than it was, so the runway above shortens even if nothing else changes.

Other Biotech/Pharma companies that filed the doubt